Building a Multi-Purpose Network for Enhanced Use of Health Information Challenges to be addressed in order to create a distributed network that can be used for CER, safety, quality

Paul Stang, PhD


Second Annual Sentinel Initiative Public Workshop

Disclaimer

- This presentation and my comments are my own and do not necessarily represent those of my employer (J&J), the broader Industry, or other groups with whom I am affiliated (OMOP).
- However, much of my thinking recently has been shaped by my work with OMOP.

The Axes of Benefit-Risk

By Perspective




THE DATA

Quality, completeness, credibility, transparency

- Data are not scarce but studies of a drug are dependent on the number of folks on the drug
- How well are *Risks* and *Benefits* captured in these data?
- What are the issues in defining events, exposures, outcomes?
- Can all those with data be 'transparent' about the characteristics of their underlying databases?
 - 'Business-sensitive' and competition issues

An Example with Dementia Definitions



Created from Erkinjuntti T, Masbye T, Steenhuis R, Hachinski V: The effect of different diagnostic criteria on the prevalence of dementia. N Engl J Med 337:1667-1774, 1997

5

THE EVIDENCE

- What is the level of 'evidence' that is appropriate for a decision and at what point in time?
 - One database, one evaluation study, at one point in time ?
 - Surveillance methods across multiple data sites?
 - What are the alternatives to the clinical trial?
- What is the ultimate decision being informed?
 - Labeling Clinical Practice
 - Product approval Reimbursement
 - Safety vs. effectiveness

WHO IS INVOLVED

- Don't try this on your own: No one stakeholder group has a monopoly on methods, data and/or insights
- Conflicts of Interest
 - financial
 - advocacy for a published position
 - those advocating use of a particular database
- Transparency in process of research and decision criteria is critical
- How will this effort be funded?

Bigger Concepts In Play

- Longitudinal thinking: these should be viewed as ongoing processes not singular studies
- Can surveillance predict full study results?
- Tension between CER and personalized medicine
- Can we define a process with meaningful measures for key decisions?
- What is the continuous learning that we can employ so that the delivery system becomes the platform for insight?
- Randomizing into the database
- Need for continuous training, education, and research

What are the next steps?

- Invest in the basic science behind the science
 - Methods for effectiveness, risk, quality
 - Definitions of exposure, outcome
 - Summarizing and communicating results from across multiple sites
- Standards in the data sources, esp in EHR
 - Systematic capture of critical data elements
 - Dealing with missing data; linkage
 - Data quality, availability, definitions
- Evidence standards: should inform action
 - What constitutes actionable evidence?
 - Transparency in what those evidence standards are
- Defining the process
- Governance and Funding Models
- Education and Training

"It's important to know what you don't know...

but could."

- H. Guess